Dashboard
Manage Tickers

JNJJOHNSON & JOHNSON

NYSE jnj.com


$ 147.94 $ 1.52 (1.04 %)    

Friday, 07-Jun-2024 13:28:02 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 465.06 $ 3.51 (0.76 %)
DIA $ 390.27 $ 2.26 (0.58 %)
SPY $ 536.11 $ 2.79 (0.52 %)
TLT $ 91.63 $ 0.00 (0.01 %)
GLD $ 213.36 $ -0.93 (-0.43 %)
$ 146.42
$ 146.66
$ 0.00 x 0
$ 150.00 x 129
$ 146.39 - $ 148.28
$ 141.57 - $ 170.63
5,016,301
na
355.82B
$ 0.49
$ 9.25
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-16-2024 12-31-2023 10-K
3 10-27-2023 10-01-2023 10-Q
4 10-27-2023 10-01-2023 10-Q
5 07-31-2023 07-02-2023 10-Q
6 04-28-2023 04-02-2023 10-Q
7 02-16-2023 01-01-2023 10-K
8 10-27-2022 10-02-2022 10-Q
9 07-29-2022 07-03-2022 10-Q
10 04-29-2022 04-03-2022 10-Q
11 02-17-2022 01-02-2022 10-K
12 10-29-2021 10-03-2021 10-Q
13 07-29-2021 07-04-2021 10-Q
14 04-30-2021 04-04-2021 10-Q
15 02-22-2021 01-03-2021 10-K
16 10-23-2020 09-27-2020 10-Q
17 07-24-2020 06-28-2020 10-Q
18 04-29-2020 03-29-2020 10-Q
19 02-18-2020 12-29-2019 10-K
20 10-28-2019 09-29-2019 10-Q
21 07-29-2019 06-30-2019 10-Q
22 05-01-2019 03-31-2019 10-Q
23 02-20-2019 12-30-2018 10-K
24 10-31-2018 09-30-2018 10-Q
25 08-02-2018 07-01-2018 10-Q
26 05-01-2018 04-01-2018 10-Q
27 02-21-2018 12-31-2017 10-K
28 11-02-2017 10-01-2017 10-Q
29 08-03-2017 07-02-2017 10-Q
30 05-08-2017 04-02-2017 10-Q
31 02-27-2017 01-01-2017 10-K
32 11-04-2016 10-02-2016 10-Q
33 08-04-2016 07-03-2016 10-Q
34 05-10-2016 04-03-2016 10-Q
35 02-24-2016 01-03-2016 10-K
36 10-30-2015 09-27-2015 10-Q
37 07-31-2015 06-28-2015 10-Q
38 05-01-2015 03-29-2015 10-Q
39 02-24-2015 12-28-2014 10-K
40 10-30-2014 09-28-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
FDA Advised Manufacturers Of Authorized Co...
06/07/2024 14:47:41

- Reuters

abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-biosimilar-industry-viability
AbbVie's Arthritis Drug Humira Retains Mar...
06/07/2024 14:39:05

Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the b...

johnson--johnson-medtechs-depuy-synthes-receives-fda-clearance-for-velys-robotic-assisted-solution-in-unicompartmental-knee-arthroplasty-uka
Johnson & Johnson MedTech's DePuy Synthes ...
06/07/2024 12:05:17

https://www.jnj.com/media-center/press-releases/depuy-synthes-receives-510k-fda-clearance-of-the-velys-robotic-assisted-solutio...

Core News & Articles
Novavax Says FDA Panel Backs Update For Mo...
06/05/2024 20:36:55

- Bloomberg

Core News & Articles
FDA Advisers Support Inclusion Of JN1 COVI...
06/05/2024 19:23:35

- Bloomberg

Core News & Articles
FDA Advisers Vote In Favor Of Recommending...
06/05/2024 18:51:23

- Reuters

johnson--johnson-submits-supplemental-nda-to-us-fda-seeking-expanded-pediatric-indication-for-hiv-1-therapy-prezcobix
Johnson & Johnson Submits Supplemental NDA...
06/04/2024 20:34:18

- Reuters

rbc-capital-reiterates-outperform-on-johnson--johnson-maintains-175-price-target
RBC Capital Reiterates Outperform on Johns...
06/04/2024 13:55:58

RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.

johnson--johnson-ordered-to-pay-260m-in-latest-talc-trial
Johnson & Johnson Ordered To Pay $260M In ...
06/04/2024 05:58:32

The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a pre...

Core News & Articles
Johnson & Johnson Announces Results From A...
06/03/2024 19:58:54

73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patien...

johnson--johnson-announces-data-from-phase-3-perseus-study-showing-darzalex-based-regimens-significantly-improve-clinical-outcomes-in-both-transplant-eligible-and--ineligible-patients-who-are-newly-diagnosed-with-multiple-myeloma
Johnson & Johnson Announces Data From Phas...
06/03/2024 19:51:26

88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-neg...

johnson--johnsons-late-breaking-results-from-its-paloma-2-study-of-subcutaneous-amivantamab-in-combination-with-lazertinib-show-clinically-meaningful-antitumor-response-and-improved-safety-profile-in-patients-with-egfr-mutated-non-small-cell-lung-cancer
Johnson & Johnson's Late-Breaking Results ...
06/03/2024 18:33:12

administration in new Phase 2 dataCHICAGO, June 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today new data from the...

johnson--johnson-at-asco-highlights-long-term-data-from-multiple-myeloma-drug-shows-sustained-deep-durable-responses-in-pretreated-patients
Johnson & Johnson At ASCO Highlights Long ...
06/03/2024 16:01:12

JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with...

performance-comparison-johnson-amp-johnson-and-competitors-in-pharmaceuticals-industry
Performance Comparison: Johnson & John...
06/03/2024 15:00:42

Core News & Articles
WATCH: Dr. Fauci Testifies Live On COVID-1...
06/03/2024 14:49:38

https://www.youtube.com/watch?v=qCsEbq9SpsM 

Core News & Articles
U.S. FDA Staff Says Covid Vaccine Makers S...
06/03/2024 14:03:33

- Reuters - Reuters 

johnson--jonshon-announced-long-term-data-from-phase-12-majestec-1-study-of-tecvayli
Johnson & Jonshon Announced Long-Term Data...
06/03/2024 12:16:51

why-sarepta-therapeutics-stock-is-rising-today
Why Sarepta Therapeutics Stock Is Rising T...
05/30/2024 18:20:54

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added ...

Core News & Articles
Sarepta Therapeutics To Join S&P Midcap 40...
05/29/2024 21:20:31

 Sarepta Therapeutics will replace Shockwave Medical in the S&P MidCap 400 effective prior to the opening of trading on Mon...

johnson--johnsons-drug-seltorexant-aces-late-stage-depression-trial
Johnson & Johnson's Drug Seltorexant Aces ...
05/29/2024 16:55:12

Johnson & Johnson reported successful Phase 3 trial results for seltorexant, an investigational treatment for major depress...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION